Search results
Results From The WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
The Society for Science began the competition in 1942 with Westinghouse Electric Corporation; for many years, the competition was known as the Westinghouse Science Talent Search. In 1998, Intel became the sponsor after it outbid several other companies. [5] In May 2016, it was announced that Regeneron Pharmaceuticals would be the new title ...
Intel and then Regeneron later assumed the title sponsorship for the Science Talent Search. [5] After graduating as valedictorian of both the Bronx High School of Science and Columbia College, Yancopoulos received his MD and PhD degrees in 1987 from Columbia University's College of Physicians & Surgeons.
The Regeneron International Science and Engineering Fair (ISEF) is an annual science fair in the United States. [1] It is owned and administered by the Society for Science, [2] a 501(c)(3) non-profit organization based in Washington, D.C. [3] Each May, more than 1800 students from roughly 75 countries and territories compete in the fair for scholarships, tuition grants, internships, scientific ...
Wolfgang Bernhard Liedtke is a German-American neurologist and corporate executive at Regeneron Pharmaceuticals in Tarrytown, New York. Within Regeneron's Global Development (Genetic Medicines), he serves as the Chair of Neurology, Psychiatry, Pain Medicine, and Sensory Systems on the Scientific Council. [1] [2] [3]
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Sanofi, in order to get out of its commitment, paid Regeneron $50 million and ceded the rights back to Regeneron. [2] The drug was a blockbuster generating $838 million in its first full year and sales increased 55% to $1.3 billion in 2013 [3] making Schleifer a billionaire. [2] In 2014 Eylea grossed $1.735 billion. [4]
This page was last edited on 14 February 2021, at 14:06 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.